Sandra D. van der Vaart's most recent trade in Laboratory Corp. Of America Holdings was a trade of 547 Common Stock done at an average price of $285.2 . Disclosure was reported to the exchange on Feb. 27, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Labcorp | Sandra D. van der Vaart | EVP, Corporate Affairs | Sale of securities on an exchange or to another person at price $ 285.19 per share. | 27 Feb 2026 | 547 | 2,578 (0%) | 0% | 285.2 | 156,000 | Common Stock |
| Labcorp | Sandra D. van der Vaart | EVP, Corporate Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2026 | 376 | 3,225 (0%) | 0% | - | Common Stock | |
| Labcorp | Sandra D. van der Vaart | EVP, Corporate Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2026 | 376 | 1,141 | - | - | Restricted Stock Unit | |
| Labcorp | Sandra D. van der Vaart | EVP, Corporate Affairs | Payment of exercise price or tax liability using portion of securities received from the company at price $ 289.89 per share. | 11 Feb 2026 | 99 | 3,126 (0%) | 0% | 289.9 | 28,699 | Common Stock |
| Labcorp | Sandra D. van der Vaart | EVP, Corporate Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2026 | 387 | 1,870 | - | - | Restricted Stock Unit | |
| Labcorp | Sandra D. van der Vaart | EVP, Corporate Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2026 | 387 | 2,690 (0%) | 0% | - | Common Stock | |
| Labcorp | Sandra D. van der Vaart | EVP, Corporate Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2026 | 353 | 1,517 | - | - | Restricted Stock Unit | |
| Labcorp | Sandra D. van der Vaart | EVP, Corporate Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2026 | 353 | 2,942 (0%) | 0% | - | Common Stock | |
| Labcorp | Sandra D. van der Vaart | EVP, Corporate Affairs | Payment of exercise price or tax liability using portion of securities received from the company at price $ 277.20 per share. | 06 Feb 2026 | 101 | 2,589 (0%) | 0% | 277.2 | 27,997 | Common Stock |
| Labcorp | Sandra D. van der Vaart | EVP, Corporate Affairs | Payment of exercise price or tax liability using portion of securities received from the company at price $ 274.01 per share. | 06 Feb 2026 | 93 | 2,849 (0%) | 0% | 274.0 | 25,483 | Common Stock |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 131.43 per share. | 13 Aug 2025 | 3,903 | 6,176 (0%) | 0% | 131.4 | 512,971 | Common Stock |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Aug 2025 | 3,903 | 0 | - | - | Non-qualified Stock Options | |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 271.42 per share. | 13 Aug 2025 | 3,903 | 2,273 (0%) | 0% | 271.4 | 1,059,371 | Common Stock |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 238.36 per share. | 01 May 2025 | 1,900 | 2,243 (0%) | 0% | 238.4 | 452,884 | Common Stock |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2025 | 3,325 | 5,495 (0%) | 0% | 0 | Common Stock | |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 231.67 per share. | 27 Mar 2025 | 1,352 | 4,143 (0%) | 0% | 231.7 | 313,218 | Common Stock |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 251.30 per share. | 25 Feb 2025 | 1,314 | 2,170 (0%) | 0% | 251.3 | 330,208 | Common Stock |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2025 | 3,400 | 3,400 | - | - | Non-qualified Stock Options | |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2025 | 1,130 | 2,580 | - | - | Restricted Stock Unit | |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2025 | 323 | 3,570 (0%) | 0% | - | Common Stock | |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2025 | 323 | 2,257 | - | - | Restricted Stock Unit | |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 245.14 per share. | 11 Feb 2025 | 86 | 3,484 (0%) | 0% | 245.1 | 21,082 | Common Stock |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2025 | 386 | 1,804 | - | - | Restricted Stock Unit | |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2025 | 386 | 3,089 (0%) | 0% | - | Common Stock | |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2025 | 354 | 3,341 (0%) | 0% | - | Common Stock | |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2025 | 354 | 1,450 | - | - | Restricted Stock Unit | |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 247.74 per share. | 06 Feb 2025 | 102 | 2,987 (0%) | 0% | 247.7 | 25,269 | Common Stock |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 246.27 per share. | 06 Feb 2025 | 94 | 3,247 (0%) | 0% | 246.3 | 23,149 | Common Stock |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 239.42 per share. | 21 Nov 2024 | 1,000 | 2,669 (0%) | 0% | 239.4 | 239,419 | Common Stock |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 227.05 per share. | 19 Aug 2024 | 2,000 | 3,669 (0%) | 0% | 227.1 | 454,100 | Common Stock |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 210.83 per share. | 14 May 2024 | 1,800 | 5,836 (0%) | 0% | 210.8 | 379,488 | Common Stock |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 210.84 per share. | 14 May 2024 | 200 | 5,636 (0%) | 0% | 210.8 | 42,167 | Common Stock |
| Labcorp | van der Vaart Sandra D. | EVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 226.45 per share. | 13 Feb 2024 | 237 | 7,636 (0%) | 0% | 226.5 | 53,669 | Common Stock |
| Labcorp | Sandra van der Vaart D. | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2024 | 324 | 8,348 | - | - | Restricted Stock Unit | |
| Labcorp | Sandra van der Vaart D. | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2024 | 324 | 7,960 (0%) | 0% | - | Common Stock | |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 227.45 per share. | 11 Feb 2024 | 87 | 7,873 (0%) | 0% | 227.4 | 19,788 | Common Stock |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 222.06 per share. | 08 Feb 2024 | 259 | 7,636 (0%) | 0% | 222.1 | 57,514 | Common Stock |
| Labcorp | D. Sandra van der Vaart | EVP, Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 3,600 | 3,600 | - | - | Non-qualified Stock Options | |
| Labcorp | Sandra van der Vaart D. | EVP, Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 1,160 | 9,025 | - | - | Restricted Stock Unit | |
| Labcorp | van der Vaart D. Sandra | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2024 | 353 | 8,672 | - | - | Restricted Stock Unit | |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2024 | 353 | 7,989 (0%) | 0% | - | Common Stock | |
| Labcorp | Sandra van der Vaart D. | EVP, Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 223.71 per share. | 06 Feb 2024 | 94 | 7,895 (0%) | 0% | 223.7 | 21,029 | Common Stock |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2024 | 264 | 7,900 (0%) | 0% | - | Common Stock | |
| Labcorp | van der Vaart D. Sandra | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2024 | 264 | 7,865 | - | - | Restricted Stock Unit | |
| Labcorp | Sandra van der Vaart D. | EVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 220.57 per share. | 02 Feb 2024 | 193 | 7,636 (0%) | 0% | 220.6 | 42,570 | Common Stock |
| Labcorp | van der Vaart Sandra D. | EVP, Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 221.54 per share. | 02 Feb 2024 | 71 | 7,829 (0%) | 0% | 221.5 | 15,729 | Common Stock |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2023 | 6,207 | 7,974 | - | - | Restricted Stock Unit | |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 240.00 per share. | 29 Jun 2023 | 212 | 7,604 (0%) | 0% | 240 | 50,880 | Common Stock |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Mar 2023 | 3,609 | 9,161 (0%) | 0% | 0 | Common Stock | |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 224.70 per share. | 30 Mar 2023 | 1,371 | 7,790 (0%) | 0% | 224.7 | 308,064 | Common Stock |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2023 | 290 | 1,767 | - | - | Restricted Stock Unit | |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2023 | 290 | 5,630 (0%) | 0% | - | Common Stock | |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 248.13 per share. | 11 Feb 2023 | 78 | 5,552 (0%) | 0% | 248.1 | 19,354 | Common Stock |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2023 | 3,000 | 3,000 | - | - | Non-qualified Stock Options | |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2023 | 950 | 2,057 | - | - | Restricted Stock Unit | |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 243.01 per share. | 07 Feb 2023 | 219 | 5,340 (0%) | 0% | 243.0 | 53,219 | Common Stock |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Feb 2023 | 300 | 1,107 | - | - | Restricted Stock Unit | |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Feb 2023 | 300 | 5,640 (0%) | 0% | - | Common Stock | |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 244.51 per share. | 04 Feb 2023 | 81 | 5,559 (0%) | 0% | 244.5 | 19,805 | Common Stock |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2023 | 237 | 1,407 | - | - | Restricted Stock Unit | |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2023 | 237 | 5,577 (0%) | 0% | - | Common Stock | |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 253.90 per share. | 02 Feb 2023 | 173 | 5,340 (0%) | 0% | 253.9 | 43,925 | Common Stock |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 254.98 per share. | 02 Feb 2023 | 64 | 5,513 (0%) | 0% | 255.0 | 16,319 | Common Stock |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 277.11 per share. | 29 Mar 2022 | 2,449 | 5,287 (0%) | 0% | 277.1 | 678,642 | Common Stock |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2022 | 4,241 | 9,528 (0%) | 0% | 0 | Common Stock | |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 276.42 per share. | 27 Mar 2022 | 1,792 | 7,736 (0%) | 0% | 276.4 | 495,345 | Common Stock |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 273.98 per share. | 15 Feb 2022 | 207 | 5,287 (0%) | 0% | 274.0 | 56,714 | Common Stock |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2022 | 3,100 | 3,100 | - | - | Non-qualified Stock Options | |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2022 | 870 | 1,928 | - | - | Restricted Stock Unit | |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2022 | 284 | 5,571 (0%) | 0% | - | Common Stock | |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2022 | 284 | 1,644 | - | - | Restricted Stock Unit | |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 272.68 per share. | 11 Feb 2022 | 77 | 5,494 (0%) | 0% | 272.7 | 20,996 | Common Stock |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Feb 2022 | 300 | 1,058 | - | - | Restricted Stock Unit | |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Feb 2022 | 300 | 5,587 (0%) | 0% | - | Common Stock | |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 277.38 per share. | 04 Feb 2022 | 218 | 5,287 (0%) | 0% | 277.4 | 60,469 | Common Stock |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 277.48 per share. | 04 Feb 2022 | 82 | 5,505 (0%) | 0% | 277.5 | 22,753 | Common Stock |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2022 | 236 | 1,358 | - | - | Restricted Stock Unit | |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2022 | 236 | 5,523 (0%) | 0% | - | Common Stock | |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 271.81 per share. | 02 Feb 2022 | 172 | 5,287 (0%) | 0% | 271.8 | 46,751 | Common Stock |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 273.19 per share. | 02 Feb 2022 | 64 | 5,459 (0%) | 0% | 273.2 | 17,484 | Common Stock |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 296.78 per share. | 15 Sep 2021 | 4,500 | 5,264 (0%) | 0% | 296.8 | 1,335,510 | Common Stock |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Sep 2021 | 4,500 | 0 | - | - | Non-qualified Stock Options | |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 84.86 per share. | 15 Sep 2021 | 4,500 | 9,764 (0%) | 0% | 84.9 | 381,870 | Common Stock |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2021 | 4,500 | 4,500 | - | - | Non-qualified Stock Options | |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 266.56 per share. | 07 Jun 2021 | 4,500 | 5,237 (0%) | 0% | 266.6 | 1,199,520 | Common Stock |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 84.86 per share. | 07 Jun 2021 | 4,500 | 9,737 (0%) | 0% | 84.9 | 381,870 | Common Stock |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 251.88 per share. | 30 Mar 2021 | 812 | 5,237 (0%) | 0% | 251.9 | 204,527 | Common Stock |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2021 | 2,310 | 6,736 (0%) | 0% | 0 | Common Stock | |
| Labcorp | Sandra D. van der Vaart | EVP, Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 251.58 per share. | 27 Mar 2021 | 687 | 6,049 (0%) | 0% | 251.6 | 172,835 | Common Stock |